Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 3, 2026, 11:36 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 138 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: osimertinib Clear all
Active, not recruiting Phase 1Phase 2 Interventional

Osimertinib and Gefitinib in EGFR Inhibitor naïve Advanced EGFR Mutant Lung Cancer

NCT03122717
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
Gefitinib, Osimertinib
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 28, 2026 · Synced Sep 3, 2026, 11:36 AM EDT
Completed Phase 1Phase 2 Interventional

JAB-3312 Based Combination Therapy in Adult Patients With Advanced Solid Tumors

NCT04720976
View directory record Official record
Conditions
Solid Tumor, NSCLC
Interventions
JAB-3312, Binimetinib, Pembrolizumab, Sotorasib, Osimertinib
Drug
Lead sponsor
Allist Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
15
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Los Angeles, California + 12 more
Source: ClinicalTrials.gov public record
Updated Apr 10, 2025 · Synced Sep 3, 2026, 11:36 AM EDT
Completed Phase 2 Interventional Results available

Local Ablative Therapy for Treatment of Oligoprogressive, EGFR-Mutated, Non-Small Cell Lung Cancer After Treatment With Osimertinib

NCT02759835
View directory record Official record
Conditions
Lung Adenocarcinoma, Lung Neoplasms
Interventions
osimertinib, Local Ablative Therapy (LAT)
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 6, 2024 · Synced Sep 3, 2026, 11:36 AM EDT
Active, not recruiting Phase 1 Interventional

A Study of the Combination of Osimertinib, Platinum and Etoposide for Patients With Metastatic EGFR Mutant Lung Cancers

NCT03567642
View directory record Official record
Conditions
Lung Cancer
Interventions
Osimertinib, Platinum, Etoposide
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 5, 2026 · Synced Sep 3, 2026, 11:36 AM EDT
Recruiting Phase 2Phase 3 Interventional

Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)

NCT07100080
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
Iza-bren, Carboplatin, Cisplatin, Pemetrexed
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
28
States / cities
Irvine, California • Orange, California • Edwards, Colorado + 22 more
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Sep 3, 2026, 11:36 AM EDT
Active, not recruiting Phase 2 Interventional

Study to Allow Patients Previously Participating in a Novartis Sponsored Trial to Continue Receiving Capmatinib Treatment as Single Agent or in Combination With Other Treatments or the Combination Treatment Alone

NCT03040973
View directory record Official record
Conditions
Advanced Solid Tumors Which Are cMET-dependent
Interventions
Capmatinib, Nazartinib, Gefitinib, Osimertinib
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 10, 2026 · Synced Sep 3, 2026, 11:36 AM EDT
Recruiting Phase 2Phase 3 Interventional

A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan, Monotherapy or in Combination With Osimertinib, Compared to Standard of Care in Adult Participants With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer

NCT07155187
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
Telisotuzumab Adizutecan, Standard of Care, Osimertinib
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
490 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
15
States / cities
Springdale, Arkansas • Duarte, California • Irvine, California + 12 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Sep 3, 2026, 11:36 AM EDT
Recruiting Phase 1 Interventional

MRX-2843 and Osimertinib for the Treatment of Advanced EGFR Mutant Non-small Cell Lung Cancer

NCT04762199
View directory record Official record
Conditions
Advanced Lung Non-Small Cell Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
Interventions
Flt3/MerTK Inhibitor MRX-2843, Osimertinib
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Mar 30, 2026 · Synced Sep 3, 2026, 11:36 AM EDT
Terminated Phase 2 Interventional Results available

Atezolizumab and Bevacizumab in EGFR Mutant NSCLC in Patients With Progressive Disease After Receiving Osimertinib

NCT04099836
View directory record Official record
Conditions
Non Small Cell Lung Cancer
Interventions
Atezolizumab, Bevacizumab
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 25, 2023 · Synced Sep 3, 2026, 11:36 AM EDT
Completed Phase 1 Interventional Results available

Study to Assess the Effect of AZD9291 on the Blood Levels of Simvastatin in Patients With EGFRm+ NSCLC

NCT02197234
View directory record Official record
Conditions
Non Small Cell Lung Cancer
Interventions
Pharmacokinetic sampling - AZD9291, Simvastatin, AZD9291 tablet dosing, Pharmacokinetic sampling - simvastatin, Pharmacokinetic sampling - AZ5140 and AZ7550
Procedure · Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2024
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Nov 19, 2025 · Synced Sep 3, 2026, 11:36 AM EDT
Recruiting Phase 2 Interventional

A Study of Stereotactic Radiosurgery (SRS) and Standard Treatment in People With Lung Cancer That Has Spread to the Brain

NCT06741085
View directory record Official record
Conditions
Non Small Cell Lung Cancer Metastatic
Interventions
osimertinib, stereotactic radiosurgery (SRS)
Drug · Radiation
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
8
States / cities
Miami, Florida • Basking Ridge, New Jersey • Middletown, New Jersey + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 16, 2026 · Synced Sep 3, 2026, 11:36 AM EDT
Completed Phase 1Phase 2 Interventional Results available

A Study of BGB324 (Bemcentinib) in Combination With Erlotinib in Patients With Non-Small Cell Lung Cancer

NCT02424617
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
Erlotinib, Bemcentinib
Drug
Lead sponsor
BerGenBio ASA
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
10
States / cities
La Jolla, California • Los Angeles, California • Tampa, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Feb 25, 2025 · Synced Sep 3, 2026, 11:36 AM EDT
Terminated Phase 3 Interventional Results available

Aumolertinib With Chemotherapy or Alone Compared With Osimertinib in Patients With Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer

NCT05493501
View directory record Official record
Conditions
NSCLC
Interventions
Aumolertinib monotherapy, Osimertinib monotherapy, Pemetrexed, Cisplatin, Carboplatin, Paclitaxel, Nab paclitaxel, Gemcitabine
Drug
Lead sponsor
EQRx International, Inc.
Industry
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
8
States / cities
Springdale, Arkansas • Hollywood, Florida • Pembroke Pines, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated May 1, 2024 · Synced Sep 3, 2026, 11:36 AM EDT
Active, not recruiting Phase 2 Interventional Results available

A Study Comparing Savolitinib Plus Osimertinib vs Savolitinib Plus Placebo in Patients With EGFRm+ and MET Amplified Advanced NSCLC

NCT04606771
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
Osimertinib + Savolitinib, Savolitinib + Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
2
States / cities
Duarte, California • Sacramento, California
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Sep 3, 2026, 11:36 AM EDT
Recruiting Phase 2Phase 3 Interventional

A Study to Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination With Osimertinib as First-Line Treatment in Adult Participants With Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer

NCT07005102
View directory record Official record
Conditions
Non-Squamous Non-Small Cell Lung Cancer
Interventions
Standard of Care, Telisotuzumab Adizutecan, Osimertinib (Osi), Cisplatin, Carboplatin, Pemetrexed
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
854 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2036
U.S. locations
14
States / cities
Chandler, Arizona • Los Angeles, California • Newport Beach, California + 11 more
Source: ClinicalTrials.gov public record
Updated Jun 7, 2026 · Synced Sep 3, 2026, 11:36 AM EDT
Active, not recruiting Phase 3 Interventional

Durvalumab With Stereotactic Body Radiation Therapy (SBRT) vs Placebo With SBRT in Early Stage Unresected Non-small Cell Lung Cancer (NSCLC) Patients/ Osimertinib Following SBRT in Patients With Early Stage Unresected NSCLC Harboring an EGFR Mutation

NCT03833154
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
Durvalumab, Placebo, (Osimertinib cohort, single-arm, open-label separate cohort)
Drug · Other
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
724 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2028
U.S. locations
80
States / cities
Tuscaloosa, Alabama • Chandler, Arizona • Phoenix, Arizona + 72 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2026 · Synced Sep 3, 2026, 11:36 AM EDT
Completed Phase 1 Interventional

Study to Assess the Blood Levels and Safety of AZD9291 in Patients With Advanced Solid Tumours and Normal Liver Function or Mild or Moderate Liver Impairment

NCT02161770
View directory record Official record
Conditions
Solid Tumours
Interventions
AZD9291 tablet dosing, Pharmacokinetic sampling - AZD9291, Pharmacokinetic sampling - AZ5140 and AZ7550
Drug · Procedure
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 99 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
5
States / cities
San Diego, California • Atlanta, Georgia • Detroit, Michigan + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 7, 2019 · Synced Sep 3, 2026, 11:36 AM EDT
Not yet recruiting Phase 1 Interventional

Osimertinib, Cetuximab, and Tucatinib for the Treatment of EGFR-Mutant Stage IV or Recurrent Non-small Lung Cell Cancer

NCT06067776
View directory record Official record
Conditions
Metastatic Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
Interventions
Cetuximab, Osimertinib, Tucatinib
Biological · Drug
Lead sponsor
Jonathan Riess
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Oct 4, 2023 · Synced Sep 3, 2026, 11:36 AM EDT
Terminated Phase 2 Interventional Results available

A Precision Medicine Approach (SMMART-ACT) for the Treatment of Patients With Advanced Sarcoma, Prostate, Breast, Ovarian or Pancreatic Cancer

NCT06630325
View directory record Official record
Conditions
Advanced Breast Carcinoma, Advanced Malignant Solid Neoplasm, Advanced Ovarian Carcinoma, Advanced Pancreatic Carcinoma, Advanced Prostate Carcinoma, Advanced Sarcoma, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Stage III Ovarian Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8, Stage III Prostate Cancer AJCC v8, Stage IV Ovarian Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8, Stage IV Prostate Cancer AJCC v8
Interventions
Abemaciclib, Biopsy, Bone Scan, Echocardiography, Exemestane, Gemcitabine, Letrozole, Multigated Acquisition Scan, Osimertinib, Pemetrexed, Survey Administration, Tamoxifen, Biospecimen Collection
Drug · Procedure · Other
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Apr 27, 2026 · Synced Sep 3, 2026, 11:36 AM EDT
Active, not recruiting Phase 2 Interventional

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

NCT02465060
View directory record Official record
Conditions
Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Bladder Carcinoma, Breast Carcinoma, Cervical Carcinoma, Colon Carcinoma, Colorectal Carcinoma, Endometrial Carcinoma, Esophageal Carcinoma, Exocrine Pancreas Carcinoma, Gastric Carcinoma, Glioma, Head and Neck Carcinoma, Hematopoietic and Lymphoid Cell Neoplasm, Kidney Carcinoma, Liver Carcinoma, Lung Carcinoma, Lymphoma, Malignant Uterine Corpus Neoplasm, Malignant Uterine Neoplasm, Melanoma, Multiple Myeloma, Ovarian Carcinoma, Prostate Carcinoma, Rectal Carcinoma, Recurrent Bladder Carcinoma, Recurrent Breast Carcinoma, Recurrent Cervical Carcinoma, Recurrent Colon Carcinoma, Recurrent Colorectal Carcinoma, Recurrent Esophageal Carcinoma, Recurrent Gastric Carcinoma, Recurrent Glioma, Recurrent Head and Neck Carcinoma, Recurrent Liver Carcinoma, Recurrent Lung Carcinoma, Recurrent Lymphoma, Recurrent Malignant Solid Neoplasm, Recurrent Malignant Uterine Corpus Neoplasm, Recurrent Melanoma, Recurrent Multiple Myeloma, Recurrent Ovarian Carcinoma, Recurrent Pancreatic Carcinoma, Recurrent Prostate Carcinoma, Recurrent Rectal Carcinoma, Recurrent Skin Carcinoma, Recurrent Thyroid Gland Carcinoma, Refractory Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Multiple Myeloma, Skin Carcinoma, Thyroid Gland Carcinoma
Interventions
Adavosertib, Afatinib, Afatinib Dimaleate, Binimetinib, Biopsy Procedure, Biospecimen Collection, Capivasertib, Computed Tomography, Copanlisib, Copanlisib Hydrochloride, Crizotinib, Cytology Specimen Collection Procedure, Dabrafenib, Dabrafenib Mesylate, Dasatinib, Defactinib, Defactinib Hydrochloride, Echocardiography Test, Erdafitinib, Fexagratinib, Ipatasertib, Laboratory Biomarker Analysis, Larotrectinib, Larotrectinib Sulfate, Magnetic Resonance Imaging, Multigated Acquisition Scan, Nivolumab, Osimertinib, Palbociclib, Pertuzumab, PI3K-beta Inhibitor GSK2636771, Radiologic Examination, Radionuclide Imaging, Relatlimab, Sapanisertib, Sunitinib Malate, Taselisib, Trametinib, Trastuzumab, Trastuzumab Emtansine, Ulixertinib, Vismodegib
Drug · Procedure · Other + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
6,452 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2026
U.S. locations
1405
States / cities
Birmingham, Alabama • Fairhope, Alabama • Mobile, Alabama + 847 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Sep 3, 2026, 11:36 AM EDT
Withdrawn No phase listed Observational

PDX Models From EGFR Mutant Tumors

NCT03872440
View directory record Official record
Conditions
Non Small Cell Lung Cancer
Interventions
Not listed
Lead sponsor
Addario Lung Cancer Medical Institute
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
San Carlos, California
Source: ClinicalTrials.gov public record
Updated Jan 8, 2020 · Synced Sep 3, 2026, 11:36 AM EDT
Active, not recruiting Phase 2 Interventional

Osimertinib and Abemaciclib in EGFR Mutant Non-Small Cell Lung Cancer After Osimertinib Resistance

NCT04545710
View directory record Official record
Conditions
Lung Cancer
Interventions
Abemaciclib, Osimertinib
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Aug 4, 2024 · Synced Sep 3, 2026, 11:36 AM EDT
Completed Phase 2 Interventional Results available

A Molecular Profiling Study of Patients With EGFR Mutation-positive Locally Advanced or Metastatic NSCLC Treated With Osimertinib

NCT03239340
View directory record Official record
Conditions
EGFR Mutation Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Interventions
Osimertinib
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
154 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
3
States / cities
Athens, Georgia • Atlanta, Georgia • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 20, 2024 · Synced Sep 3, 2026, 11:36 AM EDT
Not yet recruiting Phase 1Phase 2 Interventional

A Study to Evaluate ANS014004 in Combination With EGFR-TKI in Non-Small Cell Lung Cancer

NCT07285148
View directory record Official record
Conditions
Non-Small Cell Lung Cancer, EGFR Mutation, Metastatic Lung Cancer, MET Alteration
Interventions
ANS014004 + PLB1004, ANS014004 + Osimertinib
Drug
Lead sponsor
Beijing Pearl Biotechnology Limited Liability Company
Industry
Eligibility
18 Years and older
Enrollment
253 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 15, 2025 · Synced Sep 3, 2026, 11:36 AM EDT